Resverlogix Corp. (RVX) EPS Estimated At $-0.08

July 18, 2017 - By Peter Erickson

 Resverlogix Corp. (RVX) EPS Estimated At $ 0.08

Analysts expect Resverlogix Corp. (TSE:RVX) to report $-0.08 EPS on July, 26.They anticipate $0.04 EPS change or 33.33 % from last quarter’s $-0.12 EPS. After having $-0.16 EPS previously, Resverlogix Corp.’s analysts see -50.00 % EPS growth. The stock decreased 3.01% or $0.04 on July 17, reaching $1.29. About 86,775 shares traded. Resverlogix Corp. (TSE:RVX) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Resverlogix Corp. is a clinical-stage biotechnology company. The company has market cap of $143.63 million. The Firm is a development-stage company, which is engaged in developing apabetalone , a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. It currently has negative earnings. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.

More important recent Resverlogix Corp. (TSE:RVX) news were published by: Seekingalpha.com which released: “Resverlogix: The Science Is Getting ‘BETter’ For RVX208” on February 27, 2017, also Marketwatch.com published article titled: “1.0218”, Stockhouse.com published: “IIROC Trade Resumption – Resverlogix Corp.” on June 20, 2017. More interesting news about Resverlogix Corp. (TSE:RVX) was released by: Seekingalpha.com and their article: “Resverlogix: Analysis Of The Science Behind RVX-208” with publication date: April 08, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.